Anti-NGF Antibodies and Methods Using Same

• US 20100111970A1
• Filed: 11/16/2009
• Published: 05/06/2010
• Est. Priority Date: 12/24/2002
• Status: Active Grant

• Current Assignee: Pfizer Inc.
• Original Assignee: Pfizer Inc.
• Inventors: Rosenthal, Arnon, Pons, Jaume
• Granted Patent: US 8,088,384 B2
• Time in Patent Office: Days
• US Class Current: 424/158.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 29/02 without antiinflammatory effect
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/06 Antiarrhythmics
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.

Claims

1-33. -33. (canceled)

34. An isolated antibody or fragment thereof comprisinga heavy chain variable region comprising:

(a) the CDR1 region as shown in SEQ ID NO;

3,

(b) the CDR2 region as shown in SEQ ID NO;

4, and

(c) the CDR3 region as shown in SEQ ID NO;

5, and

2) a light chain variable region comprising;

(a) the CDR1 region as shown in SEQ ID NO;

6,

(b) the CDR2 region as shown in SEQ ID NO;

7, and

(c) the CDR3 region as shown in SEQ ID NO;

8,

wherein the antibody or fragment thereof binds human NGF.

35. The antibody or fragment thereof of claim 34, comprising

a heavy chain variable region comprising:

(a) the CDR1 region as shown in SEQ ID NO;

3,

(b) the CDR2 region as shown in SEQ ID NO;

4, and

(c) the CDR3 region as shown in SEQ ID NO;

5.

36. The antibody or fragment thereof of claim 34, comprising

a light chain variable region comprising:

(a) the CDR1 region as shown in SEQ ID NO;

6,

(b) the CDR2 region as shown in SEQ ID NO;

7, and

(c) the CDR3 region as shown in SEQ ID NO;

8.

37. The antibody or fragment thereof of claim 34, wherein the heavy chain variable region consists of the sequence as shown in SEQ ID NO:

1.

38. The antibody or fragment thereof of claim 34, wherein the light chain variable region consists of the sequence as shown in SEQ ID NO:

2.

39. The antibody of claim 34, wherein the antibody or fragment thereof is a monoclonal antibody.

40. The antibody of claim 34, wherein the antibody or fragment thereof is a humanized antibody.

41. The antibody of claim 34, wherein the antibody of fragment thereof binds human NGF with a KD of about 2 nM or less.

42. The antibody or fragment thereof of claim 41, wherein the KD is about 100 pM or less.

43. A pharmaceutical composition comprising (a) the antibody of fragment thereof of claim 34 and (b) a pharmaceutically acceptable excipient.

44. A kit comprising the antibody of fragment thereof of claim 34 and instructions for use.

45. A method of making the antibody or fragment thereof of claim 34, said method comprising expressing a polynucleotide encoding the antibody or fragment thereof of claim 34 in a host cell.

46. The antibody of claim 34, wherein the fragment is Fab, Fab′

, F(ab′

)₂, Fv, or single chain (ScFv).

47. An isolated antibody or fragment thereof comprising

a heavy chain variable region comprising:

(a) the CDR1 region as shown in SEQ ID NO;

3,

(b) the CDR2 region as shown in SEQ ID NO;

4, and

(c) the CDR3 region as shown in SEQ ID NO;

5,

wherein the antibody or fragment thereof binds human NGF.

48. The antibody of claim 47, wherein the fragment is Fab, Fab′

, F(ab′

)₂, Fv, or single chain (ScFv).

49. The antibody of claim 47, wherein the antibody or fragment thereof binds human NGF with a KD of about 2 nM or less.

50. The antibody or fragment thereof of claim 47, wherein the KD is about 100 pM or less.

51. An isolated antibody or fragment thereof comprising

a light chain variable region comprising:

(a) the CDR1 region as shown in SEQ ID NO;

6,

(b) the CDR2 region as shown in SEQ ID NO;

7, and

(c) the CDR3 region as shown in SEQ ID NO;

8,

wherein the antibody or fragment thereof binds human NGF.

52. The antibody of claim 51, wherein the fragment is Fab, Fab′

, F(ab′

)₂, Fv, or single chain (ScFv).

53. The antibody of claim 51, wherein the antibody or fragment thereof binds human NGF with a KD of about 2 nM or less.

54. The antibody or fragment thereof of claim 51, wherein the KD is about 100 pM or less.